We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Aligos (ALGS) Inks Collaboration With Merck for NASH Therapy
Read MoreHide Full Article
Aligos Therapeutics, Inc. (ALGS - Free Report) announced that it has entered into an exclusive license and collaboration agreement with pharma giant Merck (MRK - Free Report) for discovering and developing oligonucleotide candidates directed against a non-alcoholic steatohepatitis (“NASH”), using Aligos’ oligonucleotide platform technology. The companies have agreed to discover up to one additional target of interest in the cardiometabolic or fibrosis space under this deal.
Per the agreement, Aligos will receive an undisclosed upfront payment from Merck along with additional payment upon deciding on a second target therapy from the above collaboration. Aligos will also be eligible to receive up to $458 million as development-based milestones with respect to each target from the collaboration and tiered royalties on net sales, if a product is commercialized from the deal.
Notably, Aligos will evaluate the oligonucleotide molecules and deliver the optimized lead molecules, while Merck will carry out the subsequent research, clinical development and commercialization efforts.
Shares of Aligos were up 9.4% following the announcement of the deal on Monday. Meanwhile, the stock has increased 4.5% in the past month compared with the industry’s rally of 7.2%.
We note that, Aligos’ shares started trading recently on the Nasdaq Global Select Market following its initial public offering in October 2020.
While the NASH market promises potential, it is quite challenging as well. Quite a few companies are developing treatments for NASH, sparking competition in the space. Gilead Sciences (GILD - Free Report) has collaborated with Novo Nordisk (NVO - Free Report) for evaluating combination treatments to treat NASH.
Notably, Intercept Pharmaceuticals is developing obeticholic acid for the treatment of fibrosis due to NASH while clinical-stage biopharmaceutical company Galmed Pharmaceuticals Ltd. is developing Aramchol for patients with NASH and fibrosis.
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.
Image: Bigstock
Aligos (ALGS) Inks Collaboration With Merck for NASH Therapy
Aligos Therapeutics, Inc. (ALGS - Free Report) announced that it has entered into an exclusive license and collaboration agreement with pharma giant Merck (MRK - Free Report) for discovering and developing oligonucleotide candidates directed against a non-alcoholic steatohepatitis (“NASH”), using Aligos’ oligonucleotide platform technology. The companies have agreed to discover up to one additional target of interest in the cardiometabolic or fibrosis space under this deal.
Per the agreement, Aligos will receive an undisclosed upfront payment from Merck along with additional payment upon deciding on a second target therapy from the above collaboration. Aligos will also be eligible to receive up to $458 million as development-based milestones with respect to each target from the collaboration and tiered royalties on net sales, if a product is commercialized from the deal.
Notably, Aligos will evaluate the oligonucleotide molecules and deliver the optimized lead molecules, while Merck will carry out the subsequent research, clinical development and commercialization efforts.
Shares of Aligos were up 9.4% following the announcement of the deal on Monday. Meanwhile, the stock has increased 4.5% in the past month compared with the industry’s rally of 7.2%.
We note that, Aligos’ shares started trading recently on the Nasdaq Global Select Market following its initial public offering in October 2020.
While the NASH market promises potential, it is quite challenging as well. Quite a few companies are developing treatments for NASH, sparking competition in the space. Gilead Sciences (GILD - Free Report) has collaborated with Novo Nordisk (NVO - Free Report) for evaluating combination treatments to treat NASH.
Notably, Intercept Pharmaceuticals is developing obeticholic acid for the treatment of fibrosis due to NASH while clinical-stage biopharmaceutical company Galmed Pharmaceuticals Ltd. is developing Aramchol for patients with NASH and fibrosis.
Zacks Rank
Aligos currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.
See 8 breakthrough stocks now>>